Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12 Tips for Traveling With Diabetes
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
Latest
Popular
Top Rated
Type 2 Issues Archives
Print | Email | Share | Comments (4)

New Data From Phase 3 Trial Says Liraglutide Is More Effective Than Exenatide For Type 2s

Oct 27, 2008

This press release is an announcement submitted by Novo Nordisk, and was not written by Diabetes Health.

Liraglutide is under development by Novo Nordisk. It's a member of a new class of diabetes medications called GLP-1 analogues.

Novo Nordisk recently announced results from its LEAD 6 study showing that once daily liraglutide was significantly more effective at improving blood glucose control (as measured by A1c) than exenatide, a GLP-1 mimetic administered twice daily.

Liraglutide works by stimulating the release of insulin and inhibiting the release of glucagon from the liver after meals only if blood glucose levels are elevated. 

"In this study, reduction in blood glucose was greater with liraglutide than with exenatide" said Lawrence Blonde, MD, Director of the Ochsner Diabetes Clinical Research Unit in the Department of Endocrinology, Diabetes, and Metabolism at the Oxford Center in New Orleans. "Patients treated with once daily liraglutide achieved better blood glucose control and also had less minor hypoglycemia than those treated with exenatide." 

The 26-week study included 464 people with type 2 diabetes who were randomized to treatment with either liraglutide, 1.8 mg once daily, or exenatide, 10 µg twice daily, both as an add-on to their existing treatment consisting of metformin and/or a sulfonylurea. 

Nausea was the most common side effect for both treatments and was reported at a level of 25.5% in the liraglutide group and 28% in exenatide group (percent of all study participants reporting nausea at least once). However, according to the Novo Nordisk press release, in the liraglutide group, the percentage of patients reporting nausea fell each week fell to just 3% after 26 weeks. In the exenatide group, reports of nausea remained above 10% for more than 20 weeks. 

Other common gastrointestinal-related adverse events with liraglutide were diarrhea, vomiting, and dyspepsia.  

Weight loss with liraglutide is attributed to the fact that it slows gastric emptying and leads to increased satiety after meals. Liraglutide is naturally broken down in the body and does not require renal excretion. 

Source: Novo Nordisk


Categories: A1c Test, Blood Glucose, Diabetes, Diabetes, Insulin, Low Blood Sugar, Medications, Medications Research, Novo Nordisk, Type 2 Issues



You May Also Be Interested In...


Click Here To View Or Post Comments

Comments 4 comments - Oct 27, 2008

©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.